F01 for hard-to-treat moderate-to-severe lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new treatment called F01 for people with moderate-to-severe lupus that hasn't responded to other therapies. It aims to see if this experimental cell therapy can help control lupus symptoms when standard options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 65 years old.
- Diagnosed with lupus (SLE) for at least 6 months and have moderate-to-severe symptoms that haven't improved with standard treatments.
- Have active disease shown by certain blood tests (like ANA, anti-dsDNA, or anti-Smith).
- Must have tried standard lupus medications (including steroids, hydroxychloroquine, and other immune-suppressing drugs) and at least one biologic drug for at least 2 months.
- Your kidney, liver, heart, and lung function must be good enough to safely participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with lupus that has not responded well to standard treatments. It aims to reset the immune system to reduce lupus activity.
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a new treatment called CRC01, made from your own cells, for people with severe lupus that hasn't improved with standard medications. The goal is to see if it can safely control the disease and reduce symptoms.
This trial tests an experimental injection called ZM001 for people with refractory systemic lupus erythematosus (SLE) who haven't gotten better after standard treatments. It aims to see if ZM001 can help control moderate to severe disease activity.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
Hear when a new Lupus Erythematosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.